RESEARCH DIGEST / GLP-1 RECEPTOR AGONIST
Semaglutide is a GLP-1 receptor agonist studied across the diabetes, weight, heart and kidney trials.
A calm, cited reading of the published record, glycemic control first: what SUSTAIN, STEP, SELECT and FLOW actually measured, with every number pinned to its study.
The short version
Semaglutide is a once-weekly (or once-daily, in tablet form) medicine for type 2 diabetes and weight management. It copies a natural gut hormone called GLP-1 (a signal your body releases after a meal that tells the pancreas to make insulin and tells the brain you are full). Because it lasts about a week in the body, one dose keeps working for days.
In diabetes, it lowers blood sugar and trims weight. In a large weight-loss trial it cut body weight by about 15% on average. It also lowered the risk of heart attacks and strokes in people with heart disease, and slowed kidney decline in people with diabetes and kidney disease.
The trade-off is mostly the stomach: nausea, and changes in bowel habits, worst early on. What people report — including the downsides — is laid out plainly on the effects page. Nothing here is medical advice or a dose to follow.
What is semaglutide
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist — a man-made copy of the gut hormone GLP-1 that has been re-engineered to last far longer in the body [1][14]. Native GLP-1 is destroyed within about two minutes by an enzyme called DPP-4 (dipeptidyl peptidase-4, a protein-cutting enzyme in the blood). Semaglutide swaps one building block at position 8 for a non-standard amino acid (Aib) that DPP-4 cannot cut, and attaches a long fatty-acid chain that clings reversibly to albumin (the most abundant carrier protein in blood). That albumin grip shields the molecule from the kidneys and stretches its half-life to roughly one week [14].
The practical result is a medicine you can dose once a week by injection, or once a day as a tablet, rather than several times a day. It is approved across several conditions: type 2 diabetes, chronic weight management, reducing major heart events in people with established cardiovascular disease and excess weight, and, as of 2025, a form of fatty liver disease called MASH [3][13]. The pages here read each of those approvals back through the trials that earned them, starting with the glycemic (blood-sugar) evidence.
The glycemic and cardiovascular record, first
In type 2 diabetes, the headline finding is a reliable drop in HbA1c — the blood marker that reflects average glucose over about three months. Across the SUSTAIN program, once-weekly semaglutide lowered HbA1c and body weight versus placebo and versus comparator drugs, with the 2.0 mg dose lowering HbA1c more than 1.0 mg [8][11][12].
The cardiovascular evidence is what moved semaglutide from a glucose drug to a cardiometabolic one. In SUSTAIN-6, once-weekly semaglutide (0.5 or 1.0 mg) cut the combined rate of cardiovascular death, nonfatal heart attack and nonfatal stroke by 26% (hazard ratio 0.74; 95% CI 0.58-0.95) in people with type 2 diabetes at high cardiovascular risk [2]. The same trial flagged a real caution: among people who already had diabetic eye disease and whose blood sugar fell quickly, retinopathy complications were more frequent (HR 1.76) [2]. The full picture, including the safety signals, is in the Semaglutide research.
Weight, kidney and the once-weekly peptide
The same molecule that steadies blood sugar also drives substantial weight loss. In STEP 1, once-weekly subcutaneous semaglutide 2.4 mg produced a mean body-weight change of -14.9% from baseline to week 68, versus -2.4% with placebo, in adults with overweight or obesity who did not have diabetes [1]. In SELECT (n=17,604), the same 2.4 mg dose cut major adverse cardiovascular events by 20% (HR 0.80) in people with established heart disease and excess weight but no diabetes [3].
The kidney is the newest chapter. In FLOW (n=3,533), once-weekly semaglutide 1.0 mg lowered the risk of major kidney-disease events — kidney failure, a large fall in filtration, or kidney or cardiovascular death — by 24% (HR 0.76) in type 2 diabetes with chronic kidney disease [6].
As a semaglutide peptide, this is a 31-amino-acid acylated analogue of human GLP-1 — a small protein, not a small-molecule pill in the classic sense, which is why the injectable form is dosed weekly and the oral form needs a special absorption helper. How it produces all of this, from the pancreas to the appetite centers of the brain, is covered in how does semaglutide work and in semaglutide mechanism of action.